Second-line ipilimumab plus anti-PD-1 therapy ‘extends survival’
A retrospective study shows the combination improves outcomes for patients with metastatic melanoma resistant to first-line immunotherapy
Patients with metastatic melanoma resistant to anti-PD-(L)1 immune checkpoint inhibitors should be considered for combination ipilimumab plus anti-PD-1 therapy rather than ipilimumab alone, researchers say.
Professor Georgina Long of the Melanoma Institute Australia in Sydney led the retrospective cohort study, which involved 15 melanoma centres across the US and Europe, as well as Australia.
